Published: Jan 20, 2021
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Phillip Schneider and Paul Sekhri have been appointed to its board of directors. As we continue to make significant progress at Longboard, one of our top priorities is to assemble an experienced team, beginning with our leadership team and board of directors. Leveraging the decades of broad expertise and insight brought by Paul and Phil will prove invaluable as we strive to build a leading neuroscience drug development company, stated Kevin R. Lind, Longboard’s President and Chief Executive Officer.